article thumbnail

‘Proactive’ vaccine can protect against unknown future coronaviruses

Drug Discovery World

For example, the new vaccine does not include the SARS-CoV-1 coronavirus, which caused the 2003 SARS outbreak, yet it still induces an immune response to that virus. The vaccine should enter Phase I clinical trials in early 2025, but its complex nature makes it challenging to manufacture which could limit large-scale production.

Vaccine 130
article thumbnail

A personal view on antibody drug development

Drug Discovery World

Clinical trial results of those combinations and bispecifics were on numerous occasions underwhelming and didn’t stand up to their expected efficacy – not even in an additive way. We may have to explore disease complexity and signaling cascades more critically before entering costly and long clinical trial.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. “The

Trials 69
article thumbnail

AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers’Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects

The Pharma Data

Eligible patients enrolled in the trial receive treatment with AIM’s flagship pipeline drug Ampligen. The Ampligen EAP protocol is authorized to enroll up to 100 active trial participants, 20 of whom may be Long Haulers. development pipeline for ME/CFS. All study subjects will receive the same Ampligen treatments.

article thumbnail

Heroin Treatment in the UK

Common Sense for Drug Policy Blog

Prior to 2019 in England, clinically supervised HAT had only been provided as part of the Randomised Injecting Opiate Treatment Trial (RIOTT) in 2010 ( Strang et al., 2003 ) and strong results from RIOTT indicating improved outcomes for ‘treatment refractory’ people (i.e. 2009 ; Perneger, Giner, del Rio, & Mino, 1998 ; Strang et al.,

article thumbnail

China’s National Medical Products Administration approves Benlysta (belimumab) for adult patients with active lupus nephritis

The Pharma Data

The BLISS-LN phase III trial is the largest and longest trial conducted in active LN, involving 448 adult patients. About the BLISS-LN trial. It is also the first biologic in China’s 2021 National Reimbursement Drug List for paediatric SLE. About lupus.

article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

CellProthera selected the UK centres for their excellence in the conduct of clinical research with dedicated staff, equipment, availability of imaging platforms and high interest in cell therapy cardiovascular trials especially University Hospital of Birmingham equipped with a bi-plane Cathlab.

Drugs 189